OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99
Showing 26-50 of 99 citing articles:
LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study
Mine İlayda Şengör Aygün, Özben Yalçın
Clinical & Translational Oncology (2025)
Closed Access
Mine İlayda Şengör Aygün, Özben Yalçın
Clinical & Translational Oncology (2025)
Closed Access
The Role of the Tumor Microenvironment in Tumor Progression and Response to Therapy
Rafal Salim, Watheq Mohammed AL-Jewari
(2025) Vol. 1, Iss. 1, pp. 9-14
Closed Access
Rafal Salim, Watheq Mohammed AL-Jewari
(2025) Vol. 1, Iss. 1, pp. 9-14
Closed Access
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J. Randolph Hecht, Jean‐Marie Michot, David J. Bajor, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
J. Randolph Hecht, Jean‐Marie Michot, David J. Bajor, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Characterization of Exhausted T Cell Signatures in Pan-Cancer Settings
Rifat Tasnim Juthi, Saiful Arefeen Sazed, Manvita Mareboina, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2311-2311
Open Access
Rifat Tasnim Juthi, Saiful Arefeen Sazed, Manvita Mareboina, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2311-2311
Open Access
Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model
Felipe Lamenza, Peyton Roth, Puja Upadhaya, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Felipe Lamenza, Peyton Roth, Puja Upadhaya, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Identification of new immune target and signaling for cancer immunotherapy
S. P. Narote, Sharav Desai, Vipul P. Patel, et al.
Cancer Genetics (2025)
Closed Access
S. P. Narote, Sharav Desai, Vipul P. Patel, et al.
Cancer Genetics (2025)
Closed Access
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota
Ali Rahimi, Zeinab Baghernejadan, Ali Hazrati, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 186, pp. 118014-118014
Closed Access
Ali Rahimi, Zeinab Baghernejadan, Ali Hazrati, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 186, pp. 118014-118014
Closed Access
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Amirhoushang Poorkhani, Mahboubeh Tajaldini, Farahnazsadat Ahmadi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Amirhoushang Poorkhani, Mahboubeh Tajaldini, Farahnazsadat Ahmadi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Single-cell RNA-seq reveals intratumoral heterogeneity in osteosarcoma patients: A review
Dylan D. Thomas, Ryan A. Lacinski, Brock A. Lindsey
Journal of bone oncology (2023) Vol. 39, pp. 100475-100475
Open Access | Times Cited: 12
Dylan D. Thomas, Ryan A. Lacinski, Brock A. Lindsey
Journal of bone oncology (2023) Vol. 39, pp. 100475-100475
Open Access | Times Cited: 12
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, et al.
Immunotherapy (2023) Vol. 15, Iss. 8, pp. 611-618
Closed Access | Times Cited: 12
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, et al.
Immunotherapy (2023) Vol. 15, Iss. 8, pp. 611-618
Closed Access | Times Cited: 12
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Avinash Khadela, Humzah Postwala, Deval K. Rana, et al.
Medical Oncology (2023) Vol. 40, Iss. 5
Closed Access | Times Cited: 12
Avinash Khadela, Humzah Postwala, Deval K. Rana, et al.
Medical Oncology (2023) Vol. 40, Iss. 5
Closed Access | Times Cited: 12
Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer
Jeong Uk Lim, Eunyoung Lee, Sang‐Yun Lee, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 4, pp. 857-876
Open Access | Times Cited: 11
Jeong Uk Lim, Eunyoung Lee, Sang‐Yun Lee, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 4, pp. 857-876
Open Access | Times Cited: 11
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
Jacob J. Adashek
American Journal of Cancer Research (2024) Vol. 14, Iss. 1, pp. 368-377
Open Access | Times Cited: 4
Jacob J. Adashek
American Journal of Cancer Research (2024) Vol. 14, Iss. 1, pp. 368-377
Open Access | Times Cited: 4
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
José L. Blaya-Cánovas, Carmen Griñán‐Lisón, Isabel Blancas, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
José L. Blaya-Cánovas, Carmen Griñán‐Lisón, Isabel Blancas, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
Connor Frey, Mahyar Etminan
Antibodies (2024) Vol. 13, Iss. 3, pp. 59-59
Open Access | Times Cited: 4
Connor Frey, Mahyar Etminan
Antibodies (2024) Vol. 13, Iss. 3, pp. 59-59
Open Access | Times Cited: 4
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Florian Buehning, Tobias Lerchner, Julia K. Vogel, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Florian Buehning, Tobias Lerchner, Julia K. Vogel, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming
Dongkyun Kim, Giha Kim, Rongzhen Yu, et al.
Immunity (2024)
Closed Access | Times Cited: 4
Dongkyun Kim, Giha Kim, Rongzhen Yu, et al.
Immunity (2024)
Closed Access | Times Cited: 4
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
Genzui Setsu, Megumi Goto, Kentaro Ito, et al.
European Journal of Pharmacology (2023) Vol. 961, pp. 176184-176184
Closed Access | Times Cited: 10
Genzui Setsu, Megumi Goto, Kentaro Ito, et al.
European Journal of Pharmacology (2023) Vol. 961, pp. 176184-176184
Closed Access | Times Cited: 10
Many Faces of Regulatory T Cells: Heterogeneity or Plasticity?
V. G. Blinova, Dmitry D. Zhdanov
Cells (2024) Vol. 13, Iss. 11, pp. 959-959
Open Access | Times Cited: 3
V. G. Blinova, Dmitry D. Zhdanov
Cells (2024) Vol. 13, Iss. 11, pp. 959-959
Open Access | Times Cited: 3
TGF-β1 suppresses the T-cell response in teleost fish by initiating Smad3- and Foxp3-mediated transcriptional networks
Qian Zhang, Ming Geng, Kang Li, et al.
Journal of Biological Chemistry (2022) Vol. 299, Iss. 2, pp. 102843-102843
Open Access | Times Cited: 14
Qian Zhang, Ming Geng, Kang Li, et al.
Journal of Biological Chemistry (2022) Vol. 299, Iss. 2, pp. 102843-102843
Open Access | Times Cited: 14
Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort
Nuno Jorge Lamas, Sandra Lassalle, Arnaud Martel, et al.
Pathology (2023) Vol. 55, Iss. 7, pp. 929-944
Open Access | Times Cited: 7
Nuno Jorge Lamas, Sandra Lassalle, Arnaud Martel, et al.
Pathology (2023) Vol. 55, Iss. 7, pp. 929-944
Open Access | Times Cited: 7
Apoptosis, a Metabolic “Head-to-Head” between Tumor and T Cells: Implications for Immunotherapy
Ornella Franzese, Pietro Ancona, Nicoletta Bianchi, et al.
Cells (2024) Vol. 13, Iss. 11, pp. 924-924
Open Access | Times Cited: 2
Ornella Franzese, Pietro Ancona, Nicoletta Bianchi, et al.
Cells (2024) Vol. 13, Iss. 11, pp. 924-924
Open Access | Times Cited: 2
Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy
Yi Zhang, Xi Chen, Binbin Hu, et al.
Nanomedicine (2024), pp. 1-20
Closed Access | Times Cited: 2
Yi Zhang, Xi Chen, Binbin Hu, et al.
Nanomedicine (2024), pp. 1-20
Closed Access | Times Cited: 2
Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
Ryunosuke Hoshi, Kristyna A. Gorospe, Hagar I. Labouta, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1181-1181
Open Access | Times Cited: 2
Ryunosuke Hoshi, Kristyna A. Gorospe, Hagar I. Labouta, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1181-1181
Open Access | Times Cited: 2
Therapeutic antibodies in oncology: an immunopharmacological overview
Karen Toledo‐Stuardo, Carolina Ribeiro, Fabiola González‐Herrera, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 2
Karen Toledo‐Stuardo, Carolina Ribeiro, Fabiola González‐Herrera, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 2
